Munich Re's €1.7bn Profit and Strategic Amprion Exit Mask Persistent Stock Weakness
Published on 06/23/2026 at 19:02 | Redaktion boerse-global.de
On the face of it, Munich Re is firing on all cylinders. The world's largest reinsurer posted a first-quarter net profit of €1.7bn, or €13.41 a share – a sharp jump from the €8.34 per share it earned a year earlier. Its annual target of €6.3bn remains firmly on track, with management aiming for a return on equity comfortably above 18% by the end of the decade. Yet the stock continues to trade at a discount to its 200-day moving average of €528, down roughly 13% since the start of 2026 and currently hovering near €477.
One major catalyst reshaping the company's balance sheet has drawn less attention than it deserves. Munich Re's asset manager, Meag Munich Ergo, has sold its stake in the transmission grid operator Amprion as part of the M31 consortium that also includes Talanx and Swiss Life Asset Managers. The buyer is RWE, which is lifting its holding in Amprion from 25.1% to 55% for a purchase price of around €3.6bn. To fund the deal, RWE completed a capital increase on Monday, placing 74.4 million shares at €54 each with institutional investors, generating gross proceeds of roughly €4bn. For Munich Re, the exit represents a long-parked portfolio holding finally monetized – Amprion serves around 29 million customers across seven German states – and a source of cash that could be redeployed into its core reinsurance business.
That core business is being run with an increasingly hard-nosed discipline. In the April renewal season, the group deliberately let property and casualty reinsurance volume shrink by 18.5% because pricing conditions did not meet its threshold. The strategy of margin over market share has been vindicated so far by the strong quarterly earnings, but it also leaves Munich Re exposed to two big summer tests. In July, a large tranche of contracts comes up for renewal, and the company will have to defend its price floor against an industry awash with capacity. Analysts will be watching closely for any further loss of market share.
Should investors sell immediately? Or is it worth buying MĂĽnchener RĂĽck?
At the same time, the Atlantic hurricane season – rated as average by most forecasters – and the threat of severe typhoons in the Asia-Pacific region will put the group's underwriting discipline to the test. A benign storm season would help lock in the profit goals; a heavy one would test the resolve to maintain pricing power while absorbing claims.
Chart watchers, meanwhile, are looking for technical confirmation. The stock did edge back above its 38-day moving average on Monday, but the next serious hurdle sits at the 50-day line near €493. Only a clean break above the €500 psychological level would begin to repair the technical picture. Below that, the gap to the 200-day line remains about 10%.
For income-focused investors, the current valuation offers some consolation. The market expects a dividend of €25.65 a share for 2026, up from €24.00 for 2025, implying a yield of roughly 5.4% at today's price. Analysts see mean price targets of around €561 to €565, representing upside of about 18% from current levels. The next major catalyst will be the second-quarter results on 7 August, when investors will learn how the Amprion sale will affect future cash flows – and whether Munich Re can finally close the gap between its operational strength and its flagging share price.
Ad
MĂĽnchener RĂĽck Stock: New Analysis - 23 June
Fresh MĂĽnchener RĂĽck information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
